Zimmer Hip Replacement Problems | Zimmer Hip Lawsuit MDL

International Investment Bank Projects Zimmer Sales Growth

Staff Writer | March 29th, 2012

Amid reports of Zimmer hip replacement problems, ongoing multidistrict litigation, and new Zimmer hip implant lawsuit filings, an international investment bank has projected a rise in sales for Zimmer Holdings.

Projected rise in sales despite alleged Zimmer hip replacement problems

Credit Suisse, an international financial services company, indicates that Zimmer’s reputation and exposure in the joint replacement market will work to its advantage as the market bounces back from the financial recession. The company projects that Zimmer will see sales growth of 4% between 2011 and 2016, thanks to a rebound in demand for knee and hip replacements, which together account for 71% of Zimmer’s total sales.

Though Zimmer hip lawsuit filings have grown in number over the last year, with plaintiffs alleging that they suffered injuries because of Zimmer hip replacement problems, Credit Suisse also forecasts 10% growth for Zimmer Holdings, and accordingly is encouraging its investors to purchase stock. 

No indications of a Zimmer hip implant recall

Metal-on-metal implants, such as Zimmer’s Durom Cup hip device, have been the subject of Zimmer hip lawsuit filings. Plaintiffs complain of implant loosening, metallosis (a type of metal poisoning), and the need for early revision surgery.

In response to the claims, Zimmer temporarily suspended sales of its Durom Cup for three months in 2008 to investigate reports of Zimmer hip replacement problems. However, no Zimmer hip implant recall was ever issued, and Zimmer returned the product to the market.

The company maintains that its products are structurally sound and not prone to abnormal revision rates. The manufacturer claims that instances of premature dislocation in patients are due to inadequate surgical technique, rather than design defects.

In May 2011, partly in response to patient reports of Zimmer hip replacement problems, the U.S. Food and Drug Administration (FDA) ordered all metal-on-metal hip implant manufacturers to study the long-term effects of metallosis in implant recipients.

Zimmer hip MDL focussed largley on metallosis

Metallosis can occur when metal-on-metal implant components rub together, creating friction and releasing metal particles into a patient’s bloodstream and surrounding tissues. Symptoms of metallosis are varied, but many sufferers experience inflammation of the affected area and joint pain, and may eventually require hip revision surgery.

Metallosis is a common Zimmer hip lawsuit complaint, and as of June 9, 2010, the Judicial Panel on Multidistrict Litigation (JPML) ruled that there were enough cases to warrant a Zimmer hip MDL. By March 2012, the MDL, which is located in New Jersey, had grown from its original 45 cases to at least 75 cases awaiting trial.

Zimmer hip lawsuit plaintiffs claim a range of damages because of alleged Zimmer hip replacement problems and request compensation to cover past and future medical expenses, lost wages, and other damages related to the allegedly faulty implants.